NKGen Biotech, Inc. 8-K

What Happened

• NKGen Biotech, Inc. (formerly Graf Acquisition Corp. IV) filed an 8-K reporting two material financing amendments in January 2026. On January 20, 2026, NKGen and Meteora-related sellers entered into an eighth amendment to their forward purchase agreement (FPA) to extend the Valuation Date to December 31, 2026. On January 23, 2026, NKGen and its subsidiary NKGen Operating Biotech, Inc. executed a second amendment to a secured promissory note with AlpineBrook Capital GP I Limited, providing an additional $372,000 of funding.

Key Details

• FPA Amendment dated January 20, 2026 extends the Valuation Date under the OTC Equity Prepaid Forward Terms to December 31, 2026. Parties include NKGen and Meteora affiliates (Meteora Strategic Capital, MCP, MSTO).
• Alpine Second Amendment dated January 23, 2026 increases the secured note principal by $372,000 (the "Third Additional New Loan"), bringing the total principal to $26,507,106.
• The Alpine amendment clarifies that interest on the additional $372,000 accrues from January 23, 2026.
• The FPA Amendment and Alpine Second Amendment are filed as Exhibits 10.1 and 10.2 to the Form 8-K.

Why It Matters

• These are material financing developments: the FPA amendment delays the agreement’s valuation date (which affects timing of any equity settlement tied to that agreement), while the Alpine amendment increases the company’s secured indebtedness to $26.5M and starts interest accruing on the new tranche. For investors, the changes affect NKGen’s capital structure and the timing of potential equity or cash outcomes tied to the forward purchase agreement.